Table 3 Patient and fibroid characteristics evaluated using univariate analysis

Age at treatment (years)

0.63 (0.46 to 0.86)

0.003

BMI (kg/m²)

0.90 (0.64 to 1.28)

0.57

Ever pregnant (yes vs. no)

0.72 (0.34 to 1.52)

0.39

Ever live birth (yes vs. no)

0.80 (0.38 to 1.71)

0.57

Smoking history (yes vs. no)

0.45 (0.18 to 1.12)

0.09

Symptom severity score (SSS)^b

1.18 (0.87 to 1.59)

0.29

Duration of dominant symptom (months)

0.95 (0.79 to 1.15)

0.60

Pelvic pressure (yes vs. no)

0.42 (0.20 to 0.89)

0.023

Back pain (yes vs. no)

0.53 (0.13 to 2.26)

0.39

Presenting symptoms

0.94

 Bleeding only

Referent

 Bulk only

0.78 (0.27 to 2.25)

 Bleeding and bulk

0.77 (0.30 to 1.96)

 Pain (with or without bleeding or bulk)

0.76 (0.23 to 2.51)

Past medical history

Anemia (yes vs. no)

0.50 (0.22 to 1.13)

0.10

Hypertension (yes vs. no)

1.95 (0.46 to 8.36)

0.37

History of asthma (yes vs. no)

^c

0.10

History of migraines (yes vs. no)

2.00 (0.92 to 4.35)

0.08

History of pelvic or uterine surgery (yes vs. no)

2.29 (1.03 to 5.08)

0.042

Thyroid disease (yes vs. no)

1.56 (0.63 to 3.84)

0.34

Prior GnRH agonist therapy

3.92 (1.33 to 11.51)

0.013

Prior usage of oral contraceptives (yes vs. no)

2.02 (0.84 to 4.85)

0.11

Prior iron supplementation (yes vs. no)

0.63 (0.26 to 1.56)

0.32

Prior thyroid hormone therapy (yes vs. no)

1.56 (0.63 to 3.84)

0.34

Fibroid characteristic

Prior treatment (yes vs. no)

1.58 (0.71 to 3.51)

0.26

Fibroid type

0.52

 Submucosal

1.36 (0.51 to 3.65)

 Subserosal

0.4 (0.09 to 1.72)

 Transmural

0.78 (0.18 to 3.35)

 Intramural

Referent

Number of fibroids

0.029

 1

Referent

 2 to 3

0.65 (0.28 to 1.52)

 >3

0.19 (0.06 to 0.66)

Volume of largest fibroid (cm³)

0.80 (0.61 to 1.06)

0.11

Total fibroid volume (cm³)

0.70 (0.52 to 0.95)

0.022

T2 signal intensity

“Dark with min. heterogeneity” vs. all others

0.73 (0.35 to 153)

0.40

All dark vs. “isointense” and “bright”

0.85 (0.29 to 2.45)

0.76